FIELD: medicine. SUBSTANCE: the present innovation deals with methods and compositions useful to suppress αvβ5-mediated angiogenesis. The method to suppress tissue αvβ5-mediated angiogenesis applies antagonists of αvβ5-vitronectin as monoclonal antibodies, RGD- containing polypeptide and organic mimetics. The advantage of the present innovation deals with applying mentioned inhibitors, especially in case of ocular neovascular diseases. EFFECT: higher efficiency. 29 cl, 14 dwg, 10 ex, 1 tbl
Title | Year | Author | Number |
---|---|---|---|
TECHNIQUES AND COMPOSITIONS USED TO INHIBIT αβ-CAUSED ANGIOGENESIS | 1997 |
|
RU2195312C2 |
METHODS AND COMPOSITIONS USED FOR INHIBITING ANGIOGENESIS | 1997 |
|
RU2194528C2 |
METHODS AND COMPOSITION USEFUL FOR ANGIOGENESIS INHIBITION | 1995 |
|
RU2162712C2 |
METHODS FOR TREATMENT OF TUMORS AND METASTASIS USING COMBINATION OF ANTI-ANGIOGENIC THERAPY AND IMMUNOTHERAPY | 2000 |
|
RU2236251C2 |
SELECTIVE R-CADHERIN ANTAGONISTS AND METHODS | 2004 |
|
RU2349598C2 |
REVASCULARISATION OF ISCHEMIC RETINAL TISSUE AND SCREENING TECHNIQUE | 2006 |
|
RU2401124C2 |
COMPOSITIONS OF ANTIBODIES AGAINST ROR1 AND CORRESPONDING METHODS | 2017 |
|
RU2766190C2 |
POLYPEPTIDES DERIVED FROM TRYPTOPHANYL-TRNA-SYNTHETASE AND USES THEREOF IN CONTROLLING OF VASCULARISATION | 2002 |
|
RU2297425C2 |
MODULATORS OF ANGIOGENESIS AND VESSEL PERMEABILITY | 2000 |
|
RU2271216C2 |
ANTI-αvβ8 ANTIBODIES AND COMPOSITIONS AND THEIR USE | 2019 |
|
RU2812478C2 |
Authors
Dates
2003-10-20—Published
1996-08-13—Filed